• Revvity, Inc. recently opened its new In Vivo Imaging Center of Excellence in Morrisville, North Carolina, consolidating R&D teams across software, hardware, and applied biology to drive innovation in imaging systems and AI-powered tools.
• This facility positions Revvity at the forefront of scientific solutions, leveraging interdisciplinary expertise to address critical workflow challenges in disease research and accelerate next-generation technology development.
• We’ll examine how consolidating AI, imaging, and R&D talent at this center may influence Revvity’s longer-term investment narrative.

These 10 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

Revvity Investment Narrative Recap

To be a shareholder in Revvity, it's important to believe in the company's ability to generate sustainable growth from advanced scientific solutions, particularly those fueled by digital and software innovation, while navigating pressures in diagnostics pricing and unpredictable academic/government funding. The opening of the In Vivo Imaging Center in North Carolina represents a push to strengthen the long-term pipeline, though it does not appear to alter the most immediate catalyst: expanding adoption and growth in software-enabled recurring revenue. The biggest near-term risk remains exposure to regulatory and reimbursement shifts, especially in key markets like China.

Of Revvity's recent announcements, the August launch of pHSense™ reagents stands out as highly relevant, as it echoes the company's focus on next-generation drug discovery tools and workflow solutions, paralleling the imaging center’s interdisciplinary mission. These product innovations support the key catalyst of recurring revenue growth from software and consumables, which remains crucial for supporting both topline trends and margin improvement.

However, investors should also keep in mind that persistent regulatory and reimbursement uncertainties abroad may...

Revvity's narrative projects $3.3 billion in revenue and $599.9 million in earnings by 2028. This requires 5.4% yearly revenue growth and a $321.2 million earnings increase from the current $278.7 million.

Uncover how Revvity's forecasts yield a $116.81 fair value, a 41% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community members have fair value estimates for Revvity ranging from US$116.81 to US$143.91, across two separate analyses. While some see substantial upside, persistent risks around global healthcare cost pressures could limit how these expectations play out; it’s worth exploring a variety of investor perspectives on this topic.

Explore 2 other fair value estimates on Revvity - why the stock might be worth just $116.81!

Build Your Own Revvity Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Revvity research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Revvity research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Revvity's overall financial health at a glance.

Seeking Other Investments?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Find companies with promising cash flow potential yet trading below their fair value.
• We've found 18 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.